NCT00389831 - Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

December 31, 2006

Conditions

Restless Legs Syndrome

Interventions

DRUG

Rotigotine Nasal Spray

Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution

OTHER

Placebo Nasal Spray

Daily single dose of placebo delivered as single puff of nasal spray solution

Trial Locations (1)

Schwarz BioSciences GmbH, Monheim